WO2020034017A1 - Utilisation de glucose hypertonique dans des traitements dermatologiques et esthétiques - Google Patents

Utilisation de glucose hypertonique dans des traitements dermatologiques et esthétiques Download PDF

Info

Publication number
WO2020034017A1
WO2020034017A1 PCT/BR2019/050279 BR2019050279W WO2020034017A1 WO 2020034017 A1 WO2020034017 A1 WO 2020034017A1 BR 2019050279 W BR2019050279 W BR 2019050279W WO 2020034017 A1 WO2020034017 A1 WO 2020034017A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
technique
mesopro
dermatological
treatments
Prior art date
Application number
PCT/BR2019/050279
Other languages
English (en)
Portuguese (pt)
Inventor
Glades THOMASI
Original Assignee
Thomasi Glades
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomasi Glades filed Critical Thomasi Glades
Publication of WO2020034017A1 publication Critical patent/WO2020034017A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • the present invention belongs to the technological sector of regenerative medicine and refers, more specifically, to a substance with hypertonic glucose of second use to be used in the mesopro technique, particularly for dermatological and aesthetic treatments; and the method of applying that substance.
  • Prolotherapy is widely used in regenerative medicine, reduces pain while repairing and strengthens joint tissues affected in chronic musculoskeletal injuries. It treats muscle, tendon or ligament dislocations, strains, injuries or ruptures, as well as chronic pain and stiffness from osteoarthritis, or chronic low back pain.
  • treatment consists of a series of injections of a solution of chemical irritant and combination substances, applied over two to six weeks, with intervals between them. The number of injections varies depending on the individual and the medical condition being treated. Effective as a treatment, it can provide pain relief for a long time or even permanently.
  • prolotherapy is similar to the technique presented in the present invention, however it is not reported in the state of the art tests on the skin, nor changes in the scalp or in skin diseases with the application of prolotherapy.
  • the mesopro technique of the present invention differs from prolotherapy also in the application to the muscles, since in addition to toning, which does not do prolotherapy, mesopro can also increase the muscle at the application site if desired, with different concentrations of the mixture .
  • the endopeel has a treatment developed with the objective of regenerating tensioning the skin in areas that for years tend to fall, creating sagging and wrinkles on the skin, acting only on the muscle and not directly on the skin.
  • the procedure causes cauterization in the muscles, generating retraction and not toning and stimulation of new cells, and thus only softens the skin, improves the contours and harmonizes the characteristics, which is why it does not increase the volume of the face or distort the patient's characteristics.
  • this technique has a higher risk of allergic reactions and glottis edema, something that does not occur in the technique of the present invention.
  • ALLEN HOOPER - Randomized controlled trial for the treatment of chronic dorsal wrist pain with dextrose prolotherapy - July 18, 2013, we compared the results of treatment of chronic pain in the dorsal wrist with lidocaine in relation to the lidocaine / dextrose injection, and injections were administered monthly, with doses in the periscaphoid and perilunate ligaments, using a splashing technique, for a total of 1 ml in each location, with 1% lidocaine or a mixture of 0.60 lidocaine % and 20% dextrose.
  • the mesopro technique presents a solution using a composition of hypertonic glucose different from the aforementioned techniques, and demonstrates itself as a solution for several dermatological and aesthetic pathologies such as scars, open pores, sagging skin and muscle, baldness, scleroderma in plaque, breast augmentation, buttock augmentation, fibrous scars, post-liposuction fibrosis, fat recovery, among others.
  • the present invention relates to the use of hypertonic glucose through a technique called mesopro, which is intended for its application for dermatological and aesthetic treatments.
  • mesopro a technique intended for its application for dermatological and aesthetic treatments.
  • hypertonic glucose is used, which despite being already known in the technological sector of regenerative medicine and for dermatological and aesthetic clinical purposes, the present invention covers a new range of concentrations of the hypertonic glucose substance and a technique for its use which can be applied in other parts of the human body, where such use is not known in the state of the art bringing novelty in this area.
  • the mesopro technique can be considered a proliferative technique, that is, where it is applied it will cause a cell structure identical to the one that was stimulated with the application.
  • hypertonic glucose is shown with a differentiated substance to those already known as phenol, polydocanol, liquid pumice, silicon and various mixtures of products because it is not toxic or allergenic, has the lowest rates of side effects and superior results compared to other techniques with multiple uses, such as Plasma Rich in Platelets (PPR), Dermarroler, Laser among others already mentioned.
  • this technique does not produce allergies and does not present toxicity, however if the patient is allergic to the mescal anesthetic, it can be removed without detriment to the results in the treatment. Depending on the degree of inflammation of the tissue, it can be increased or decreased according to the concentration of the mixture and the amount applied and the extent of the tissue / structure to undergo the puncture. In addition, there is a significant improvement aesthetic changes and the resolution of pathologies that have not been successful so far, such as plaque scleroderma, where elasticity, color, alteration of the skin's relief occurs and if applied in depth to muscle and fat, these also recover. Finally, it is seen that these advances are not achieved with other means of treatment currently known.
  • the present invention proposes the use of a substance with efficacy in dermatological and aesthetic treatments, through the mesopro technique.
  • the most important substance in this technique is hypertonic glucose, which at concentrations above 5% has the power to ignite tissue; this inflammation causes the organism to produce regenerating chemicals at the application site. Because it is a proliferative technique, it resembles a stem cell stimulus, but differs in cells identical to those that were stimulated with glucose puncture.
  • the mesopro technique is intended to treat deforming skin conditions such as sclerotherapy, acne scars, surgical scars or syphilis scars; in skin aesthetics in addition to the scars of wrinkles and sagging; filling areas where fat has been absorbed by aging, disease or surgery.
  • this substance can be used to improve the repilation of alopecia sites such as the scalp, eyebrows or eyelashes and to increase muscle tone and volume.
  • hypertonic glucose that works with concentrations of 5% to 75%, however the ideal margin is 50% to 75%. Hypertonic glucose concentrations below 5% are not effective for the treatment of pathologies proposed in the present invention.
  • the present invention has an innovative technique, and for its application in dermatological and aesthetic treatments, some essential materials are needed, which do not limit the invention and its use, and materials can be used in addition to the models mentioned such as: anesthetic ointment, which should be applied to relieve the pain from the bites; injection syringe; needle, to remove the material from the ampoule; needle with a light diameter preferably of 30G 1 ⁇ 2 for the application of glucose to the skin, or electronic pistols, manual pistols, stamps or the basic syringe with a needle, in order to mitigate the discomfort of applying the product on the skin; cleaning material of the place to be applied the technique and finally hypertonic glucose, preferably containing an amount of 75% glucose, 4% lidocaine and qsp of a chemically stable vehicle for the composition.
  • hypertonic glucose preferably containing an amount of 75% glucose, 4% lidocaine and qsp of a chemically stable vehicle for the composition.
  • Example 1 On the skin, the punctures should preferably be between 60 and 90 degrees in relation to the biological tissue, with spacing of 0.3 cm to 1 cm when performed on the skin, while when performed on the muscle the spacing should be greater or the amount per point should be less.
  • 3 units can be applied every 1.5 cm of muscle extension; if it is an orbicularis muscle of the eyes, which is smaller in relation to the calf muscles, 1 unit is performed every 2 cm.
  • the amount of liquid applied at each puncture can vary from 1 to 5 units.
  • the reapplication may be repeated every 2 weeks or more, depending on the reaction of each patient, if carried out before the appropriate time for each person, it may lead to tissue injury and not to its improvement, but it is preferable to apply it every 2 months.
  • the substance is injected into the basal layer, and cannot be superficial so as not to chemically burn the epithelial tissue.
  • the puncture becomes painless due to anesthetic ointment. Around 5 seconds after the puncture comes a burning sensation in the place. This sensation lasts for approximately 15 seconds.
  • the formation of a papule in the tissue is observed, as if it were an insect bite and after about 1 minute these papules begin to unite and become one the entire application site becomes swollen .
  • the edema varies according to the reaction of each patient and usually persists for 48 hours; after that time, the edema quickly reduces, and may vary from 5 to 10 days to resolve completely.
  • Example 2 In muscle, application in bodybuilding serves to increase toning and volume. To improve sagging, hypertonic glucose should be placed close to the muscle insertion area, and in the muscle several punctures with few units of hypertonic glucose. If an increase in muscle volume is desired, the application must be done with greater spacing and with more units of hypertonic glucose per puncture, it can be modified according to the experience of the applicator.
  • Example 3 For fibrosis in general, such as in liposuction powders, fillings and surgical cuts. Hypertonic glucose is placed around the fibrotic tissue and very little inside it, at least until it is more elastic and soft. It can be started with 1 unit within fibrosis and spacing around 0.5 cm, or according to the applicator's experience.
  • Example 4 For baldness, the application should be done with a 30g 1 ⁇ 2 needle or needles suitable for mesotherapy guns or specific needles for mesotherapy. On average, 3 units of the mixture are placed every 0.3 to 0.5 cm from the area to be treated. Apply to an intermediate depth of the hair follicle, because too deep becomes too painful and unnecessary to obtain result. Scalp papules will be painful for up to 14 days, varying from person to person.
  • Example 5 For the volume and pexy of the breasts, hypertonic glucose is first applied to the skin of the breasts and must also cover the frontal chest area above the breasts, at least in the area of the band corresponding to the breasts and going up to the neck ; to increase the volume, place the same hypertonic glucose in the fat layer and mammary gland, always aiming at the harmonious shape.
  • Example 6 For plaque scleroderma, the application of hypertonic glucose should be done over the entire length of the lesion and its depth. Starting with the skin and then the muscles. It facilitates the visualization of the inflammatory reaction and the amount to be placed in the muscles as well as their spacing can be more accurately calculated.
  • Example 7 Finally, to fill in fat, to correct places where there was excessive removal of fat or there was absorption of fat with anesthetic results or to improve areas of scar adhesion.
  • This specification describes a substance for use in the mesopro technique, more precisely hypertonic glucose for dermatological and aesthetic treatments using the mesopro technique, endowed with novelty, inventive activity, descriptive and demonstrative sufficiency, industrial application and, consequently, covered with all the essential requirements for granting the privilege claimed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

De manière générale, la présente invention relève du secteur technologique de la médecine régénérative et concerne, plus particulièrement, une substance avec glucose hypertonique de seconde utilisation destinée à la technique « mesopro », notamment pour des traitements dermatologiques et esthétiques. La présente invention concerne l'utilisation de glucose hypertonique dans une plage de 50% à 75% pour application dans des traitements de pathologies déformantes de la peau, notamment la sclérothérapie en plaque, les cicatrices d'acné, les cicatrices chirurgicales ou les cicatrices de la syphilis; dans l'esthétique de la peau en plus des cicatrices des rides et de la flaccidité; pour le remplissage de régions où la graisse a été absorbée à cause du vieillissement, d'une maladie ou de chirurgies; pour augmenter la pilosité à des emplacements favorisant l'alopécie, tels que le cuir chevelu, les sourcils ou les cils, et pour augmenter le tonus et le volume des muscles. Par ailleurs, la présente invention concerne l'utilisation de la technique « mesopro », les éléments suivants étant utilisés: pommade anesthésiante, seringue d'injection, aiguille pour application et retrait de la substance de l'ampoule, glucose hypertonique pouvant contenir de préférence un anesthésiant et une substance désinfectante.
PCT/BR2019/050279 2018-08-13 2019-07-17 Utilisation de glucose hypertonique dans des traitements dermatologiques et esthétiques WO2020034017A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102018016528-3A BR102018016528A2 (pt) 2018-08-13 2018-08-13 Uso de glicose hipertônica em tratamentos dermatológicos e estéticos
BRBR1020180165283 2018-08-13

Publications (1)

Publication Number Publication Date
WO2020034017A1 true WO2020034017A1 (fr) 2020-02-20

Family

ID=69524527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2019/050279 WO2020034017A1 (fr) 2018-08-13 2019-07-17 Utilisation de glucose hypertonique dans des traitements dermatologiques et esthétiques

Country Status (2)

Country Link
BR (1) BR102018016528A2 (fr)
WO (1) WO2020034017A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098638A (zh) * 1993-08-07 1995-02-15 章贤君 一种新戒毒合剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098638A (zh) * 1993-08-07 1995-02-15 章贤君 一种新戒毒合剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERTANHA, M ET AL.: "Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial", TRIALS 2014, vol. 15, no. 497, 19 December 2014 (2014-12-19), pages 1 - 6, XP021207069 *
SHIMOOKA, T ET AL.: "Increase in Water Permeability of Negatively Charged Liposomal Membrane by Local Anesthetics", CHEM. PHARM. BULL., vol. 40, no. 7, 25 July 1992 (1992-07-25), pages 1880 - 1882, XP000255623 *

Also Published As

Publication number Publication date
BR102018016528A2 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
Yamazaki et al. Linear polarized infrared irradiation using Super Lizer™ is an effective treatment for multiple‐type alopecia areata
ELLER et al. Skin peeling and scarification: in the treatment of pitted scars, pigmentations and certain facial blemishes
KR20200020658A (ko) 피부의 미용적 외모
Choi et al. Edema and pain reduction using transcutaneous electrical nerve stimulation treatment
Levy et al. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone
Beatini et al. Hyaluronic acid hybrid cooperative complexes and the BAP (Bio Aesthetic Points) technique: the new edge in biorejuvenation
ES2541177A2 (es) Formulación cosmética de uso tópico con capacidad de regeneración dérmica, epidérmica y antiarrugas
WO2020034017A1 (fr) Utilisation de glucose hypertonique dans des traitements dermatologiques et esthétiques
Lima et al. Percutaneous Collagen Induction with Microneedling
RU2576084C1 (ru) Способ профилактики и устранения изменений кожи лица, вызванных старением
CN110582264B (zh) 眼睑皮肤状况的处理方法
RU2284176C2 (ru) Способ лечения больных с миофасциальным болевым дисфункциональным синдромом
KR101129415B1 (ko) 발 마사지 크림 화장품 조성물
WO2015111034A1 (fr) Appareil et procédés de traitement de la peau, d'application d'un médicament et de formulation d'une crème
RU2286791C1 (ru) Способ лечения рубцов
CN113226281B (zh) 一种精油组合物及其制备方法和应用
KR20200070684A (ko) 파스
Tenenbaum et al. Cosmetic Dermatology
Twisy Subcision with Platelet-Rich Plasma and Microneedling versus Subcision with Saline and Microneedling in Posttraumatic Scars
RU2626599C2 (ru) Способ лечения воспалительных заболеваний опорно-двигательного аппарата у крупного рогатого скота
Thamizharasan et al. Cosmetic Devices
Lima et al. Correcting Post-burn Scar Using PCI
KR20200094372A (ko) 허리 통증 치료용 약용 고제
KR20240043446A (ko) 탈모방지를 위한 기능성 두피 유효성분 흡수유도 장치
Satish et al. Upanaha Sveda and its modification-A Critical Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19849285

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19849285

Country of ref document: EP

Kind code of ref document: A1